Holen Sie sich die Stockscreener-App
1.71
1.16%
-0.02
Handel nachbörslich:
1.71
Schlusskurs vom Vortag:
$1.73
Offen:
$1.73
24-Stunden-Volumen:
75,322
Relative Volume:
0.32
Marktkapitalisierung:
$127.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-19.57M
KGV:
-0.5463
EPS:
-3.13
Netto-Cashflow:
$-17.24M
1W Leistung:
-7.07%
1M Leistung:
+6.87%
6M Leistung:
-22.27%
1J Leistung:
+26.67%
1-Tages-Spanne:
$1.655
$1.73
1-Wochen-Bereich:
$1.655
$1.85
52-Wochen-Spanne:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Firmenname
Inhibikase Therapeutics Inc
Sektor
Branche
Telefon
(302) 295-3800
Adresse
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Vergleichen Sie IKT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.71 | 131.15M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-12 | Herabstufung | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
Published on: 2025-09-03 08:54:14 - Newser
Analyzing drawdowns of Inhibikase Therapeutics Inc. with statistical toolsGlobal Markets & Risk Controlled Daily Plans - Newser
Relative strength of Inhibikase Therapeutics Inc. in sector analysisWeekly Stock Report & High Return Trade Guides - Newser
Using portfolio simulators with Inhibikase Therapeutics Inc. includedCEO Change & Entry Point Strategy Guides - Newser
What earnings revisions data tells us about Inhibikase Therapeutics Inc.Quarterly Portfolio Report & Community Supported Trade Ideas - Newser
Should you hold or exit Inhibikase Therapeutics Inc. nowJuly 2025 Trends & Technical Analysis for Trade Confirmation - Newser
Will Inhibikase Therapeutics Inc. benefit from macro trendsJuly 2025 Review & Long Hold Capital Preservation Plans - Newser
Measuring Inhibikase Therapeutics Inc.’s beta against major indices2025 Trade Ideas & Daily Profit Focused Stock Screening - Newser
What is the earnings history of Inhibikase Therapeutics Inc.July 2025 Market Mood & Reliable Breakout Stock Forecasts - khodrobank.com
Does Inhibikase Therapeutics Inc. outperform in volatile markets2025 Short Interest & AI Driven Price Predictions - khodrobank.com
Is Inhibikase Therapeutics Inc. affected by consumer sentimentEarnings Growth Summary & Safe Capital Allocation Plans - khodrobank.com
What is the next catalyst for Inhibikase Therapeutics Inc.Portfolio Value Summary & Free High Accuracy Swing Entry Alerts - khodrobank.com
Is Inhibikase Therapeutics Inc. a stock for growth or value investorsJuly 2025 Sector Moves & Weekly Chart Analysis and Guides - khodrobank.com
Using RSI to spot recovery in Inhibikase Therapeutics Inc.Earnings Recap Summary & Reliable Entry Point Trade Alerts - Newser
Can Inhibikase Therapeutics Inc. hit a new high this monthStop Loss & Momentum Based Trading Signals - Newser
Reversal indicators forming on Inhibikase Therapeutics Inc. stock2025 Institutional Moves & Community Consensus Picks - Newser
What are analysts’ price targets for Inhibikase Therapeutics Inc.2025 Geopolitical Influence & Verified Short-Term Plans - khodrobank.com
Is a relief rally coming for Inhibikase Therapeutics Inc. holdersTrade Risk Report & Daily Price Action Insights - Newser
Published on: 2025-09-01 22:20:55 - Newser
Is it time to cut losses on Inhibikase Therapeutics Inc.July 2025 PostEarnings & Weekly Watchlist for Hot Stocks - Newser
Is Inhibikase Therapeutics Inc. undervalued by DCF analysis2025 Technical Overview & Smart Swing Trading Techniques - khodrobank.com
Is Inhibikase Therapeutics Inc. forming bullish engulfing patternsWeekly Gains Summary & Fast Moving Market Watchlists - khodrobank.com
Parkinson's Disease Pipeline Analysis, 2025 by DelveInsight | - openPR.com
Parkinson’s Disease Pipeline Analysis, 2025 by DelveInsight | Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, - Barchart.com
Using R and stats models for Inhibikase Therapeutics Inc. forecastingQuarterly Trade Summary & Weekly High Return Stock Opportunities - Newser
Using Python tools to backtest Inhibikase Therapeutics Inc. strategiesJuly 2025 Trade Ideas & Smart Swing Trading Techniques - Newser
Is Inhibikase Therapeutics Inc. stock a smart retirement pick2025 Historical Comparison & Free AI Powered Buy and Sell Recommendations - khodrobank.com
Inhibikase Therapeutics (NASDAQ:IKT) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Published on: 2025-08-31 22:05:17 - Newser
Ranking Inhibikase Therapeutics Inc. among high performing stocks via tools2025 Big Picture & Weekly High Return Opportunities - Newser
How institutional ownership impacts Inhibikase Therapeutics Inc. stockJuly 2025 Levels & Technical Entry and Exit Tips - Newser
Live market analysis of Inhibikase Therapeutics Inc.2025 Stock Rankings & Smart Money Movement Tracker - Newser
How high can Inhibikase Therapeutics Inc. stock goJuly 2025 Action & Stepwise Trade Signal Implementation - Newser
Is Inhibikase Therapeutics Inc. affected by consumer sentiment getLinesFromResByArray error: size == 0 - sisain.net
Is Inhibikase Therapeutics Inc. Forming a Consolidation Base getLinesFromResByArray error: size == 0 - thegnnews.com
Applying Elliott Wave Theory to Inhibikase Therapeutics Inc.Market Growth Report & Technical Entry and Exit Alerts - Newser
Finanzdaten der Inhibikase Therapeutics Inc-Aktie (IKT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Inhibikase Therapeutics Inc-Aktie (IKT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):